Semaglutide is a synthetic GLP-1 receptor agonist with roughly 94 percent homology to endogenous GLP-1, a 31 amino acid peptide that mimics the incretin released from L cells in the gut. The same molecule appears under several brand names: Ozempic, approved in 2017 for type two diabetes; Wegovy, approved in 2021 for obesity; and Rybelsus, the oral formulation approved in 2019 for type two diabetes. This lesson works through the mechanisms, the trial evidence, and the practical titration that shapes how clinicians apply it.

How it works

Activity begins at the GLP-1 receptor through a Gs protein that raises cyclic AMP, driving PKA, CREB phosphorylation, and glucose-dependent insulin secretion from the beta cell. Insulin release here is glucose dependent, so the liver retains its ability to mount gluconeogenesis during a hypoglycemic event. Alpha cell glucagon is suppressed in the same glucose-dependent manner, reducing hepatic glucose output. Central pathways through POMC and CART neurons reduce hunger signaling, while delayed gastric emptying prolongs nutrient absorption and postprandial satiety.

Beyond glycemic effects, GLP-1 receptors on cardiomyocytes and endothelium support anti-inflammatory and anti-atherogenic activity. Dr. Seeds frames the deeper mechanisms around AMPK and mTOR balance, NFKB suppression of pro-inflammatory cytokines, and NFR2 activation of antioxidant transcription. RAS modulation in the kidney contributes natriuresis and anti-fibrotic action. A C18 fatty diacid modification improves albumin binding and extends the half life to about 168 hours, enabling weekly subcutaneous dosing. The oral form uses a SNAC absorption enhancer to overcome low peptide bioavailability.

Evidence and clinical use

Multiple randomized controlled programs inform its use, including SUSTAIN, STEP, SELECT, and FLOW. The SELECT trial enrolled close to 18,000 patients with established cardiovascular disease and BMI above 27 but no diabetes, and showed a 20 percent MACE reduction with cardiovascular benefit independent of A1C change. FLOW demonstrated renal benefit. Semaglutide was the first anti-obesity GLP-1 to show cardiovascular event reduction.

Dr. Seeds emphasizes slow, tailored titration starting at 0.25 mg weekly, advancing gradually and using weight trend as a guide. The aim is roughly 0.5 to 0.75 pounds of loss per week to help preserve muscle mass and aesthetics. Going slowly can reduce the nausea and GI effects that accompany dose escalation. Clinicians should review the black box warning for thyroid C cell tumors, screen for medullary thyroid carcinoma and MEN type two, monitor for pancreatitis and gallbladder events, schedule baseline and yearly eye exams given retinopathy signals, and discontinue before pregnancy.

Key clinical points

• Insulin secretion and glucagon suppression are glucose dependent, which lowers the risk of driving frank hypoglycemia from the drug alone.
• SELECT and FLOW extend the evidence to cardiovascular and renal benefit beyond glycemic control.
• Slow, patient-specific titration can reduce GI effects and help preserve muscle mass during weight loss.
• Baseline and yearly eye exams, plus monitoring for pancreatitis and gallbladder events, support safer use.
• Durable results depend on pairing therapy with sleep, nutrition, and resistance training, since weight regain is common after discontinuation.